Insider Transactions in Q2 2025 at Akero Therapeutics, Inc. (AKRO)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 24
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,250
-3.55%
|
$256,250
$41.03 P/Share
|
|
Apr 24
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+3.43%
|
$131,250
$21.1 P/Share
|
|
Apr 15
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
9,073
-4.4%
|
$344,774
$38.21 P/Share
|
|
Apr 15
2025
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,073
+8.02%
|
$190,533
$21.1 P/Share
|
|
Apr 10
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-4.58%
|
$1,050,000
$35.23 P/Share
|
|
Apr 07
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,250
-0.9%
|
$225,000
$36.56 P/Share
|
|
Apr 07
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+3.43%
|
$131,250
$21.1 P/Share
|